Compare AbCellera Biologics Inc (ABCL) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Sibanye Stillwater Ltd — how do they compare? AbCellera Biologics Inc trades at $7.2 (market cap $2.35B), while Sibanye Stillwater Ltd trades at $8.26 (market cap $5.98B). The key difference: Sibanye Stillwater Ltd is far larger — about 2.5× AbCellera Biologics Inc's market cap, and Sibanye Stillwater Ltd pays a 3.65% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | SBSW | |
|---|---|---|
Market Cap | $2.35B | $5.98B |
Sector | Health | Basic Materials |
52-Week High | $8.12 | $21.12 |
52-Week Low | $2.78 | $7.27 |
Enterprise Value | $1.99B | $7.60B |
Dividend Yield | — | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Sibanye Stillwater (SBSW) trades at $8.52, down 4.91% today, with a bearish technical signal and negative earnings trends. The company reported a net loss of $7.30 billion in 2024, though revenue remains substantial at $112.13 billion. Recent news highlights operational improvements, including a surge in EBITDA and management's debt reduction targets, but profitability challenges persist.
The outlook is mixed: low valuation multiples suggest potential upside if operational turnaround succeeds, but negative margins and high debt pose significant risks. Analyst sentiment leans bullish with 42.86% buy ratings, yet recent earnings misses and cash flow volatility warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
